• Mashup Score: 0
    Shirish M Gadgeel MD on Pembrolizumab Plus Chemotherapy for Metastatic NSCLC 5 Year Follow up - The ASCO Post - 7 month(s) ago

    Shirish M. Gadgeel, MD, of the Henry Ford Cancer Institute, discusses a 5-year follow-up study of patients with metastatic non–small cell lung cancer (NSCLC) who were treated with pembrolizumab plus chemotherapy. According to Dr. Gadgeel, the findings continue to support the use of pembrolizumab plus chemotherapy as a standard-of-care first-line treatment, including in tumors with a PD-L1 tumor proportion scores of less than 1%. Seshiru Nakazawa, MD, PhD, of Dana-Farber Cancer Institute, discusses

    Source: ascopost.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      Shirish M. Gadgeel, MD, on Pembrolizumab Plus Chemotherapy for Metastatic NSCLC: 5-Year Follow-up https://t.co/5R3NGEYd38 #LCSM #lungcancer #oncology #WCLC23 @ShirishGadgeel @HenryFordNews @HenryFordHealth

  • Mashup Score: 0
    MET fusions as a therapeutic target in NSCLC - 7 month(s) ago

    Chul Kim, MD, MPH, Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC, discusses how MET alterations that lead to MET pathway activation are an important characteristic of various types of cancer, including non-small cell lung cancer (NSCLC), and how MET fusions are a potential therapeutic target. Dr Kim shares findings on the prevalence of MET fusions in different cancers, where MET fusions were seen in about 0.1% of cases of NSCLC and almost exclusively in lung adenocarcinomas. It was also concluded that there are potentially two categories of MET fusion: primary driver mutations or secondary acquired resistance mutations. Dr Kim also highlights the clinical importance of this research as evidenced by MET fusion-positive patients with NSCLC exhibiting a shorter overall survival rate compared to MET fusion-negative NSCLC patients. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore. These works are owned by Magda

    Source: www.vjoncology.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      🎥@chulkimMD from @LombardiCancer sheds light on the significance of MET fusions in cancer, particularly in #NSCLC, with insights into their prevalence and clinical implications 🫁 ➡️https://t.co/ol9tyNXbLv⬅️ #WCLC23 #LCSM #LungCancer

  • Mashup Score: 0
    Multidisciplinary consensus for the definition of resectable NSCLC - 7 month(s) ago

    Mariana Brandao, MD, PhD, Institute Jules Bordet, Brussels, Belgium, discusses the current consensus on the definition of resectable stage III non-small cell lung cancer (NSCLC). In recent years, multiple clinical trials have been conducted to examine the neoadjuvant combination of chemotherapy and immunotherapy for patients with NSCLC. A frequent difficulty in these trials is the lack of definition for resectable tumours and the European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group proposed the development of a multidisciplinary consensus to classify resectable NSCLC. Data was collected through an international survey, a systematic literature review, and over 100 cases of patients with stage III NSCLC for clinicians to review. The main findings of the consensus indicated that certain critical structures such as the oesophagus are completely unresectable, and tumours with limited lymph node involvement (such as N1 and N0 tumours) are resectable. Dr Branda

    Source: www.vjoncology.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      🎥@MarianaBrandao0 of @JulesBordet addresses the challenge of defining resectable stage III #NSCLC, highlighting a multidisciplinary consensus for clearer criteria: ➡️https://t.co/6pgoV5vpAu⬅️ #LCSM #LungCancer #WCLC23

  • Mashup Score: 0
    Yasir Y Elamin MD on Brigatinib in ALK Rearranged Metastatic Non Small Cell Lung Cancer - The ASCO Post - 7 month(s) ago

    Yasir Y. Elamin, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from the BRIGHTSTAR study, in which brigatinib with local consoli dative therapy was found to be safe in patients with ALK -rearranged advanced non–small cell lung cancer. This regimen yielded promising outcomes when compared with historical outcomes with brigatinib alone (Abstract OA22.04). Tom E. Stinchcombe, MD, of Duke Cancer Institute, discusses an analysis of the rate of second primary lung cancer from the

    Source: ascopost.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      Yasir Y. Elamin, MD, on Brigatinib in ALK-Rearranged Metastatic Non–Small Cell Lung Cancer https://t.co/e8PfG6yJVO #LCSM #lungcancer #WCLC23 #oncology @MDAndersonNews

  • Mashup Score: 3
    2023 WCLC Highlights | IASLC - 7 month(s) ago

    Dr. Navneet Singh, MD DM (India) will moderate the program and lead the discussion and Q&A following panel presentations by Christian Rolfo, MD, Ph.D., MBA (USA …

    Source: www.iaslc.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of IASLC
      IASLC

      Join us next week for the upcoming IASLC Webinar: "2023 WCLC Highlights" w/@ns_chd, @ChristianRolfo, @cbaldotto & @HendriksLizza to discuss EGFRm advanced #NSCLC (FLAURA2), I-SABR study, AEGEAN & much more! https://t.co/DIeKJqLXwC #LCSM #WCLC23 https://t.co/75Etw5dS6x

  • Mashup Score: 1
    Chee K Lee PhD MBBS on Durvalumab Tremelimumab and Chemotherapy in NSCLC - The ASCO Post - 7 month(s) ago

    Chee K. Lee, PhD, MBBS, of the University of Sydney, discusses findings of the ILLUMINATE study, which showed d urvalumab and tremelimuma b with chemotherapy yielded antitumor activity in patients with non–small cell lung cancer (NSCLC) whose tumors progressed after receiving EGFR inhibitors. This result was especially marked in those with EGFR T790M–negative tumors (Abstract OA09.04). Seshiru Nakazawa, MD, PhD, of Dana-Farber Cancer Institute, discusses activating the MET tyrosine kinase domain mutation,

    Source: ascopost.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      Chee K. Lee, PhD, MBBS, on Durvalumab, Tremelimumab, and Chemotherapy in NSCLC https://t.co/9SFx47UX8r #LCSM #lungcancer #WCLC23 #oncology #immunotherapy @Sydney_Uni

  • Mashup Score: 0
    David H Harpole Jr MD on Perioperative Durvalumab Plus Chemotherapy in Resectable NSCLC - The ASCO Post - 7 month(s) ago

    David H. Harpole, Jr, MD, of Duke University Medical Center, discusses further exploratory analyses of patients with EGFR -mutated resectable non–small cell lung cancer (NSCLC) enrolled in the phase III AEGEAN study. In this trial, perioperative durvalumab plus neoadjuvant chemotherapy, vs neoadjuvant chemotherapy alone, significantly improved event-free survival and pathologic complete response (Abstract OA12.06). Tom E. Stinchcombe, MD, of Duke Cancer Institute, discusses an analysis of the rate of

    Source: ascopost.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      David H. Harpole, Jr, MD, on Perioperative Durvalumab Plus Chemotherapy in Resectable NSCLC https://t.co/M74zYZZy9B #LCSM #lungcancer #oncology @DukeHealth #WCLC23 @IASLC

Load More